What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives

Published:2023-10-04 Issue:43 Volume:44 Page:4499-4502
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Sabouret Pierre¹²^ORCID,Ecarnot Fiona³⁴^ORCID,De Rosa Salvatore⁵^ORCID,Ray Kausik K⁶^ORCID

Affiliation:

1. Heart Institute and Action Group, Pitié-Salpétrière, Sorbonne University , Paris , France

2. National College of French Cardiologists , 13 rue Niepce, 75014 Paris , France

3. Department of Cardiology, University Hospital Besancon , Boulevard Fleming, 25000 Besançon , France

4. EA3920, Université de Franche-Comté , 1 Rue Claude Goudimel, 25000 Besançon , France

5. Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro , Catanzaro , Italy

6. Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College , London , UK

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/44/43/4499/53403712/ehad632.pdf

Reference10 articles.

1. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes;Lim;Eur J Prev Cardiol,2023

2. Diabetes, metformin and glucose lowering therapies after myocardial infarction: insights from the SWEDEHEART registry;Ritsinger;Diab Vasc Dis Res,2020

3. An overview of GLP-1 agonists and recent cardiovascular outcomes trials;Sheahan;Postgrad Med J,2020

4. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes;Marx;Circulation,2022

5. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes;Quast;Diabetes Obes Metab,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide;Journal of Cardiovascular Medicine;2024-06-21

2. Targeting obesity for therapeutic intervention in heart failure patients;Expert Review of Cardiovascular Therapy;2024-06-02

3. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance;Cardiovascular Diabetology;2024-03-11

4. Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists;Polish Archives of Internal Medicine;2024-01-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3